Trial · NCT03350347
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Hb (Hemoglobin) level | From week 30 to 36 | |
| Primary | Change in hemoglobin level from baseline to the average during the evaluation period | Baseline and week 30 to 36 | |
| Secondary | Responder rate: proportion of responders among the subjects | From week 30 to 36 | Responder is defined as meeting all of the following criteria: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
| Secondary | Proportion of subjects who meet each component of the response | From week 30 to 36 | Response: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
| Secondary | Hb level | Baseline and up to 52 weeks | |
| Secondary | Change in Hb level | Baseline and up to 52 weeks | |
| Secondary | Proportion of subjects whose mean hemoglobin levels are in the target range during the evaluation period | From week 30 to 36 | |
| Secondary | Proportion of subjects whose mean hemoglobin levels are above the target range during the evaluation period | From week 30 to 36 | |
| Secondary | Proportion of subjects whose mean hemoglobin levels are below the target range during the evaluation period | From week 30 to 36 | |
| Secondary | Proportion of subjects whose hemoglobin levels are in the target range | Up to 52 weeks | |
| Secondary | Proportion of subjects whose hemoglobin levels are above the target range | Up to 52 weeks | |
| Secondary | Proportion of subjects whose hemoglobin levels are below the target range | Up to 52 weeks | |
| Secondary | Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week | Up to 52 weeks | Defined as change in Hb level / duration between two visits (weeks) |
| Secondary | Number of participants with serious adverse events | Up to 52 weeks | |
| Secondary | Maximum concentration (Cmax) of Molidustat | At baseline, week 12, week 24 and week 52 | |
| Secondary | Area under the concentration-time curve (AUC) of Molidustat | At baseline, week 12, week 24 and week 52 | |
| Secondary | EPO (Erythropoietin) serum concentration of Molidustat | At baseline, week 12, week 24 and week 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03350347/registered